Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 3/20 | 0.73 |
| ▸ | TNK2 | Q07912 | 17/20 | 0.70 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.56 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20628279 | 0.87 | PIK3CD (0.74) | DCLK1TNK2MAPK7LRRK2PIK3CD | |
| SCHEMBL17469567 | 0.85 | DCLK1 (1.00) | DCLK1MAPK7LRRK2PIK3CDAURKA | |
| SCHEMBL20628380 | 0.82 | TNK2 (0.75) | TNK2MAPK7LRRK2PIK3CDPIK3C2G | |
| SCHEMBL16065775 | 0.82 | TNK2 (1.00) | TNK2MAPK7LRRK2 | |
| SCHEMBL20628387 | 0.81 | PIK3CD (0.75) | DCLK1TNK2MAPK7LRRK2PIK3CD | |
| SCHEMBL16065860 | 0.80 | TNK2 (0.76) | DCLK1TNK2LRRK2PIK3CDAURKA | |
| SCHEMBL16065800 | 0.79 | TNK2 (0.62) | TNK2MAPK7LRRK2 | |
| SCHEMBL16065780 | 0.79 | TNK2 (1.00) | DCLK1TNK2MAPK7LRRK2 | |
| SCHEMBL20094144 | 0.78 | DCLK1 (0.80) | DCLK1TNK2MAPK7LRRK2PIK3CD | |
| SCHEMBL21938134 | 0.77 | DCLK1 (0.68) | DCLK1TNK2MAPK7LRRK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | DCLK1 796/4885TNK2 125/4885MAPK7 112/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | DCLK1 796/4885TNK2 125/4885MAPK7 112/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | DCLK1 1387/4885TNK2 60/4885MAPK7 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.